Table 3 Primary, Secondary, and Exploratory Outcome Variables (Intent-to-Treat Analysis)
From: Review of Desloratadine Data Using the ARIA Guidelines
| Â | 5-mg DL | Placebo | P | ||
|---|---|---|---|---|---|
|  | Baseline LS (m ± SEM) | Days 1-15 LS (m ± SEM) | Baseline LS (m ± SEM) | Days 1-15 LS (m ± SEM) |  |
AM/PM T5SS reflective | 8.71 ± 0.15 | -3.19 ± 0.22 | 8.49 ± 0.15 | -2.29 ± 0.22 | <0.001 |
RQLQ total score (at end point) | 2.96 ± 0.08 | -1.10 ± 0.10 | 2.80 ± 0.08 | -0.73 ± 0.10 | <0.001 |
AM/PM T5SS instantaneous | 8.30 ± 0.17 | -2.86 ± 0.20 | 8.17 ± 0.17 | -1.90 ± 0.20 | <0.001 |
AM/PM rhinorrhea reflective | 1.81 ± -0.04 | -0.58 ± 0.05 | 1.75 ± 0.04 | -0.38 ± 0.05 | <0.001 |
AM/PM nasal congestion reflective | 1.96 ± 0.04 | -0.56 ± 0.05 | 1.87 ± 0.04 | -0.43 ± 0.05 | 0.013 |
AM/PM sneezing reflective | 1.65 ± 0.04 | -0.64 ± 0.05 | 1.61 ± 0.04 | -0.42 ± 0.05 | <0.011 |
AM/PM nasal itching reflective | 1.7 ± 0.04 | -0.67 ± 0.05 | 1.65 ± 0.04 | -0.43 ± 0.05 | <0.001 |
AM/PM eye itching reflective | 1.38 ± 0.06 | -0.58 ± 0.05 | 1.45 ± 0.06 | -0.46 ± 0.05 | 0.047 |
AM/PM rhinorrhea instantaneous | 1.76 ± 0.05 | -0.54 ± 0.05 | 1.72 ± 0.05 | -0.33 ± 0.05 | <0.001 |
AM/PM nasal congestion instantaneous | 1.94 ± 0.05 | -0.52 ± 0.05 | 1.87 ± 0.05 | -0.39 ± 0.05 | 0.009 |
AM/PM sneezing instantaneous | 1.56 ± 0.05 | -0.59 ± 0.05 | 1.51 ± 0.05 | -0.36 ± 0.05 | <0.001 |
AM/PM nasal itching instantaneous | 1.65 ± 0.05 | -0.63 ± 0.05 | 1.61 ± 0.05 | -0.37 ± 0.05 | <0.001 |
AM/PM eye itching instantaneous | 1.38 ± 0.06 | -0.58 ± 0.05 | 1.46 ± 0.06 | -0.45 ± 0.05 | 0.023 |
Sleep interference | 1.37 ± 0.06 | -0.39 ± 0.05 | 1.38 ± 0.06 | -0.27 ± 0.05 | 0.039 |
Activity interference | 1.72 ± 0.05 | -0.60 ± 0.06 | 1.66 ± 0.05 | -0.40 ± 0.06 | <0.001 |
Symptom severity reflective (VAS) | 57.4 ± 1.36 | -17.2 ± 1.50 | 56.76 ± 1.35 | -10.9 ± 1.49 | <0.001 |
Patient's evaluation of response WPAI-AS | NA | 3.24 ± -0.10 | NA | 3.66 ± - 0.10 | <0.001 |
overall work impairment | 46.38 ± 2.35 | -15.0 ± 2.78 | 41.37 ± 2.27 | -5.7 ± 2.69 | 0.002 |
activity impairment | 48.24 ± 1.85 | -15.3 ± 2.20 | 46.04 ± 1.87 | -9.2 ± 2.22 | 0.007 |